189 related articles for article (PubMed ID: 38642130)
21. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
23. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
24. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
[TBL] [Abstract][Full Text] [Related]
25. Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.
Oumi N; Itamochi H; Komatsu H; Oishi T; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Kudoh A; Harada T
Hum Cell; 2016 Jan; 29(1):46-51. PubMed ID: 26070481
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
[TBL] [Abstract][Full Text] [Related]
28. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
Nash A; Creaney J
Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
30. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
31. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
[TBL] [Abstract][Full Text] [Related]
32. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
[TBL] [Abstract][Full Text] [Related]
34. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
35. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
36. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
[TBL] [Abstract][Full Text] [Related]
37. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Kalra N; Ashai A; Xi L; Zhang J; Avital I; Raffeld M; Hassan R
Oncol Rep; 2012 Jun; 27(6):1794-800. PubMed ID: 22426987
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy.
Foote MB; Shia J; Zauderer MG; Nash GM; Cercek A
J Immunother; 2022 Feb-Mar 01; 45(2):100-103. PubMed ID: 34723916
[TBL] [Abstract][Full Text] [Related]
39. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.
Sheffield BS; Tinker AV; Shen Y; Hwang H; Li-Chang HH; Pleasance E; Ch'ng C; Lum A; Lorette J; McConnell YJ; Sun S; Jones SJ; Gown AM; Huntsman DG; Schaeffer DF; Churg A; Yip S; Laskin J; Marra MA
PLoS One; 2015; 10(3):e0119689. PubMed ID: 25798586
[TBL] [Abstract][Full Text] [Related]
40. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
Jhanwar SC; Xu XL; Elahi AH; Abramson DH
Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]